Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Viridian Therapeutics Inc (NQ: VRDN )

14.41 -0.06 (-0.41%)
Streaming Delayed Price Updated: 10:44 AM EDT, Jul 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 74,847
Open 14.67
Bid (Size) 14.39 (5)
Ask (Size) 14.43 (1)
Prev. Close 14.47
Today's Range 14.31 - 14.92
52wk Range 10.93 - 24.18
Shares Outstanding 9,587,155
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
Expert Ratings For Viridian Therapeutics
Via Benzinga

Performance

YTD
-35.53%
-35.53%
1 Month
+14.64%
+14.64%
3 Month
+0.77%
+0.77%
6 Month
-27.95%
-27.95%
1 Year
-28.38%
-28.38%

More News

Read More
3 Small-Cap Stocks With Explosive 2X Growth Potential
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
7 Analysts Assess Viridian Therapeutics: What You Need To Know
Via Benzinga
Unveiling 4 Analyst Insights On Viridian Therapeutics
Via Benzinga
Navigating 6 Analyst Ratings For Viridian Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in Upcoming May Investor Conferences
From Viridian Therapeutics, Inc.
Via Business Wire
VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Finding the Next Big Winners: 3 Stocks You Can Snag for Under $20
Via InvestorPlace
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer
From Viridian Therapeutics, Inc.
Via Business Wire
Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Viridian Therapeutics, Inc.
Via Business Wire
Here's Why Viridian Therapeutics (VRDN) Stock Is Moving
Via Benzinga
Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock
From Viridian Therapeutics, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.